Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elapegademase - Leadiant Biosciences

Next Previous
Drug Profile

Elapegademase - Leadiant Biosciences

Alternative Names: elapegademase-lvlr; EZN-2279; LB-601; PEG-rADA; Pegademase recombinant - Leadiant Biosciences; Pegylated recombinant adenosine deaminase; Polyethylene glycol recombinant adenosine deaminase; Revcovi; STM-279

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sigma-Tau Pharmaceuticals
  • Developer Leadiant Biosciences; Teijin Pharma
  • Class Antivirals; Polyethylene glycols; Skin disorder therapies
  • Mechanism of Action Adenosine deaminase replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenosine deaminase deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adenosine deaminase deficiency
  • No development reported Scleroderma

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for preclinical development in Scleroderma in USA
  • 12 Feb 2020 Launched for Adenosine deaminase deficiency (In children, In the elderly, In adults) in USA (IM)
  • 01 Jun 2019 Preclinical trials in Scleroderma in USA (unspecified route) (Leadiant Biosciences pipeline, June 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top